Cellular immune response – Page 4 – Communicable Diseases Research

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

Article

Published on 2022-10-042022-11-15
Journal: PLoS Pathogens [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] Activation antibody Antibody Response Antibody titre antigen exposure baseline benefit binding BNT162b2 boost CD4+ T cell CD8+ Cellular immune response clinical trial Course COVID-19 Delta dose ELISA ELISPOT enhanced global public health glycoprotein Heterologous highest humoral immune memory immune response immunological increase in individual majority marker median mRNA mRNA COVID-19 vaccine mRNA vaccination mRNA vaccine naïve natural infection neutralising antibody titre omicron participant Participants PCR proportion question receiving recruited response RNA SARS-CoV-2 vaccine second dose seroconverted significantly higher subject the SARS-CoV-2 titre vaccination Vaccination strategy Vaccine variants were measured wildtype
[DOI] 10.1371/journal.ppat.1010885 PMC 바로가기

Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers

Article

Published on 2022-10-032022-11-15
Journal: Pathogens and disease [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] assays B-cell baseline booster booster vaccines cellular Cellular immune response convalescent convalescent individual Coronavirus-2 determine ELISA ELISPOT ELISpot IFN-γ release assay first dose Health care worker health care workers hospital humoral humoral immune responses Humoral immunity IFN-γ IgG level IgG responses immune individual individuals interferon-γ janssen mounted mRNA mRNA vaccine natural immunity Netherlands occurred offer pandemic Pfizer postvaccination receiving recipient responses SARS-CoV-2 serological seronegative seropositive severe disease spike-specific cellular immunity Support T-cell T-cell Response vaccination Vaccine variants of concern vector vaccine Virus neutralization VNT waned
[DOI] 10.1093/femspd/ftac035 PMC 바로가기

NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses

Article

Published on 2022-10-032022-11-15
Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 진단, 치료기술,

Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients

Article

Published on 2022-10-012023-07-09
Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] COVID19(2023년),

[키워드] anti-CD20 Cellular immune response COVID-19 multiple sclerosis Ocrelizumab SARS-CoV-2
[DOI] 10.1177/13524585221102158

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern

Article

Published on 2022-10-012022-11-15
Journal: ESMO open [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] anti-SARS-CoV-2 Anti-spike antibody BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine BNT162b2 vaccine booster Cancer cancer patient cell-mediated immune Cellular immune response Concentration COVID-19 delta variant dose evaluated follow-up period highest highlight Hospitalization humoral Immunoglobulin Infection interferon-γ interquartile range longitudinal cohort study lowest median Messenger RNA Neutralizing Neutralizing activity neutralizing antibody of BNT162b2 omicron Oxygen therapy Patient positive response reduced reduction in required SARS-CoV-2 serum Seven solid tumor subject the SARS-CoV-2 third dose Treatment triggering Vaccine variant variants of concern VOCs were measured were used whole blood sample wild-type strain
[DOI] 10.1016/j.esmoop.2022.100574 PMC 바로가기

A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection

Article

Published on 2022-09-282022-11-15
Journal: Journal of Virology [Category] SARS, 변종, 신종인플루엔자, 진단,

[키워드] Amino acid animal Bivalent bivalent vaccine C-terminal Cellular immune response conserved contagious COVID-19 Delta delta variant develop domain Ebola ectodomain Efficacy Evidence fused global public health glycoprotein H1N1 H3N2 hamster humoral immunization infections Infectious disease Influenza influenza A virus Influenza virus influenza viruses M2 protein mice Neutralizing neutralizing antibody Point mutation PROTECT Protein provide recombinant reduced Respiratory disease respiratory droplet respiratory viral S2 domain SARS-CoV-2 SARS-CoV-2 Delta variant SARS-CoV-2 SP SARS-CoV-2 variant shown significantly Spike protein the RBD threat transmitted Vaccine vaccine candidate vaccine platform variant vesicular stomatitis virus VSV VSV vector
[DOI] 10.1128/jvi.01337-22 PMC 바로가기

The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition

Article

Published on 2022-09-212022-11-15
Journal: Nature Communications [Category] SARS, 변종, 진단, 치료제,

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study

Article

Published on 2022-09-142022-11-15
Journal: Scientific Reports [Category] SARS, 진단, 치료기술,

Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains

Article

Published on 2022-09-122022-11-15
Journal: Viruses [Category] SARS, 변종, 진단, 치료기술,

A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity

Article

Published on 2022-09-072022-11-15
Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] addition amplified Antibody Response antigen expression attenuate B.1.351 B.1.617.2 Beta caused CD3 CD4 CD8 cell-mediated immune Cell-mediated immunity Cellular immune response Convalescent patients COVID-19 COVID-19 vaccine cytokine response Delta disease severity displaying dual-antigen saRNA vaccine elicit hamsters humoral immune response induce lower dose mice mRNA vaccine mutated N antigen Neutralizing antibody response Neutralizing antibody titer PROTECT Proteins RNA RNA vaccine S-RBD SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants self-amplifying RNA spike T cell Th1 vaccination variant variants of concern Viral load
[DOI] 10.1016/j.ymthe.2022.04.014 PMC 바로가기